•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Accutane
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Did you experience any of the following side effects? (Check all that apply.)




If you gave birth while taking Accutane/Soriatane, was your child born with birth defects? Please describe:

Please further describe side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

SA Popular Acne Treatment Could Cause Aggressiveness

Nov 4, 2002 | SABC News, South Africa The US Food and Drug Administration (FDA) has added "aggressive and/or violent behaviours" to its list of possible adverse effects resulting from the intake of Accutane, a potent drug prescribed for the treatment of acne.

Marketed in South Africa as Roaccutane, the drug's ability to treat severe nodal acne that does not respond to other treatments has ensured its ready acceptance and popular use here. However, the latest amendment of the safety information regarding the drug might put this ready acceptance on hold for a while.

Yesterday, Stephen Toovey, the medical director of MedInfo, urged medical practitioners and patients to take heed of the new amendments. "A statement has been added to the US package insert regarding the long-term use of isotretinoin (Roaccutane), advising that the drug be given at the recommended doses for no longer than the recommended duration.

"I believe that this advice is important and should not be ignored," he said.

The latest revision of the safety information from the US follows earlier warnings, published in 1998, of possible adverse reactions to the drug. Those warnings confirmed that patients on Roaccutane evidence increased incidence of depression, psychosis and suicidal thoughts and actions.

Although an exact causal relationship could not be established, several patients have reported that the depression subsided when they stopped taking the drug.